CA2550135A1 - Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante - Google Patents

Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante Download PDF

Info

Publication number: CA2550135A1
Authority: CA; Canada
Prior art keywords: disease; mutations; mtdna; disorder; biological sample
Prior art date: 2003-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002550135A

Other languages

English (en)

Inventor

Mark Birch-Machin

Gabriel D. Dakubo

Ryan Parr

Robert Thayer

Alioune Ngom

John Th'ng

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genesis Genomics Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-11

Filing date

2004-12-13

Publication date

2005-06-23

2003-12-11 Priority claimed from US10/732,374 external-priority patent/US20050026167A1/en

2004-12-13 Application filed by Individual filed Critical Individual

2005-06-23 Publication of CA2550135A1 publication Critical patent/CA2550135A1/fr

Status Abandoned legal-status Critical Current

Links

230000002438 mitochondrial effect Effects 0.000 title claims abstract description 20
230000036541 health Effects 0.000 title description 11
230000035772 mutation Effects 0.000 claims abstract description 271
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 257
201000010099 disease Diseases 0.000 claims abstract description 180
238000012217 deletion Methods 0.000 claims abstract description 105
230000037430 deletion Effects 0.000 claims abstract description 105
230000032683 aging Effects 0.000 claims abstract description 67
208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 54
206010060862 Prostate cancer Diseases 0.000 claims abstract description 51
201000008261 skin carcinoma Diseases 0.000 claims abstract description 28
238000003780 insertion Methods 0.000 claims abstract description 9
230000037431 insertion Effects 0.000 claims abstract description 9
108020005196 Mitochondrial DNA Proteins 0.000 claims description 244
206010028980 Neoplasm Diseases 0.000 claims description 155
238000000034 method Methods 0.000 claims description 128
108020004414 DNA Proteins 0.000 claims description 103
150000007523 nucleic acids Chemical class 0.000 claims description 95
210000001519 tissue Anatomy 0.000 claims description 92
102000039446 nucleic acids Human genes 0.000 claims description 90
108020004707 nucleic acids Proteins 0.000 claims description 90
208000035475 disorder Diseases 0.000 claims description 77
239000012472 biological sample Substances 0.000 claims description 69
230000009826 neoplastic cell growth Effects 0.000 claims description 61
241000282414 Homo sapiens Species 0.000 claims description 60
239000000523 sample Substances 0.000 claims description 56
201000011510 cancer Diseases 0.000 claims description 53
239000007787 solid Substances 0.000 claims description 45
238000009396 hybridization Methods 0.000 claims description 43
238000001514 detection method Methods 0.000 claims description 40
230000008774 maternal effect Effects 0.000 claims description 35
238000012163 sequencing technique Methods 0.000 claims description 34
239000000758 substrate Substances 0.000 claims description 27
108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
230000036210 malignancy Effects 0.000 claims description 26
238000002493 microarray Methods 0.000 claims description 21
108090000623 proteins and genes Proteins 0.000 claims description 21
238000003745 diagnosis Methods 0.000 claims description 20
238000004458 analytical method Methods 0.000 claims description 18
238000012544 monitoring process Methods 0.000 claims description 12
238000004128 high performance liquid chromatography Methods 0.000 claims description 11
108091034117 Oligonucleotide Proteins 0.000 claims description 10
239000002299 complementary DNA Substances 0.000 claims description 10
230000002159 abnormal effect Effects 0.000 claims description 9
238000000605 extraction Methods 0.000 claims description 9
238000000018 DNA microarray Methods 0.000 claims description 8
210000001124 body fluid Anatomy 0.000 claims description 8
238000006467 substitution reaction Methods 0.000 claims description 7
239000003147 molecular marker Substances 0.000 claims description 5
238000001899 southwestern blot Methods 0.000 claims description 5
238000002105 Southern blotting Methods 0.000 claims description 3
238000001262 western blot Methods 0.000 claims description 3
238000000636 Northern blotting Methods 0.000 claims description 2
230000007773 growth pattern Effects 0.000 claims description 2
230000007704 transition Effects 0.000 abstract description 8
238000005215 recombination Methods 0.000 abstract description 5
230000006798 recombination Effects 0.000 abstract description 5
230000008707 rearrangement Effects 0.000 abstract description 3
210000003470 mitochondria Anatomy 0.000 description 140
238000003752 polymerase chain reaction Methods 0.000 description 77
239000013615 primer Substances 0.000 description 56
108091033319 polynucleotide Proteins 0.000 description 51
102000040430 polynucleotide Human genes 0.000 description 51
239000002157 polynucleotide Substances 0.000 description 51
210000002307 prostate Anatomy 0.000 description 39
210000004027 cell Anatomy 0.000 description 36
239000012530 fluid Substances 0.000 description 24
230000003211 malignant effect Effects 0.000 description 22
230000003321 amplification Effects 0.000 description 19
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
238000003199 nucleic acid amplification method Methods 0.000 description 19
239000000047 product Substances 0.000 description 18
210000003491 skin Anatomy 0.000 description 17
230000001965 increasing effect Effects 0.000 description 15
239000002773 nucleotide Substances 0.000 description 14
125000003729 nucleotide group Chemical group 0.000 description 14
230000003902 lesion Effects 0.000 description 13
239000002243 precursor Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 13
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
230000006378 damage Effects 0.000 description 12
238000011161 development Methods 0.000 description 12
230000018109 developmental process Effects 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
230000000295 complement effect Effects 0.000 description 11
239000012634 fragment Substances 0.000 description 11
208000000453 Skin Neoplasms Diseases 0.000 description 10
239000000872 buffer Substances 0.000 description 10
238000011160 research Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
238000003491 array Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000002068 genetic effect Effects 0.000 description 9
230000008569 process Effects 0.000 description 9
238000001712 DNA sequencing Methods 0.000 description 8
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
102000007066 Prostate-Specific Antigen Human genes 0.000 description 8
108010072866 Prostate-Specific Antigen Proteins 0.000 description 8
238000013188 needle biopsy Methods 0.000 description 8
201000000849 skin cancer Diseases 0.000 description 8
239000000090 biomarker Substances 0.000 description 7
238000001574 biopsy Methods 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
229920000915 polyvinyl chloride Polymers 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
206010004146 Basal cell carcinoma Diseases 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
108091092724 Noncoding DNA Proteins 0.000 description 6
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
210000004907 gland Anatomy 0.000 description 6
239000003550 marker Substances 0.000 description 6
-1 oxygen free radical Chemical class 0.000 description 6
238000003753 real-time PCR Methods 0.000 description 6
238000012216 screening Methods 0.000 description 6
206010041823 squamous cell carcinoma Diseases 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
206010069754 Acquired gene mutation Diseases 0.000 description 5
206010061818 Disease progression Diseases 0.000 description 5
241000208125 Nicotiana Species 0.000 description 5
235000002637 Nicotiana tabacum Nutrition 0.000 description 5
208000009621 actinic keratosis Diseases 0.000 description 5
230000004075 alteration Effects 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
230000005750 disease progression Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000000869 mutational effect Effects 0.000 description 5
238000003499 nucleic acid array Methods 0.000 description 5
102000054765 polymorphisms of proteins Human genes 0.000 description 5
238000004393 prognosis Methods 0.000 description 5
239000003642 reactive oxygen metabolite Substances 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
210000004927 skin cell Anatomy 0.000 description 5
230000037439 somatic mutation Effects 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
102000002322 Egg Proteins Human genes 0.000 description 4
108010000912 Egg Proteins Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
208000004403 Prostatic Hyperplasia Diseases 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
238000000137 annealing Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000027455 binding Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
210000002615 epidermis Anatomy 0.000 description 4
210000004209 hair Anatomy 0.000 description 4
238000000370 laser capture micro-dissection Methods 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
239000003471 mutagenic agent Substances 0.000 description 4
231100000707 mutagenic chemical Toxicity 0.000 description 4
210000004681 ovum Anatomy 0.000 description 4
230000010627 oxidative phosphorylation Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000036561 sun exposure Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
238000011282 treatment Methods 0.000 description 4
208000013165 Bowen disease Diseases 0.000 description 3
208000019337 Bowen disease of the skin Diseases 0.000 description 3
239000003155 DNA primer Substances 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
108010067770 Endopeptidase K Proteins 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
206010061309 Neoplasm progression Diseases 0.000 description 3
108091093105 Nuclear DNA Proteins 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
235000014676 Phragmites communis Nutrition 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
108700025695 Suppressor Genes Proteins 0.000 description 3
240000006365 Vitis vinifera Species 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000004891 communication Methods 0.000 description 3
238000007405 data analysis Methods 0.000 description 3
230000007547 defect Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
230000003862 health status Effects 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000003463 organelle Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000005267 prostate cell Anatomy 0.000 description 3
238000011471 prostatectomy Methods 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
230000000391 smoking effect Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
230000002407 ATP formation Effects 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000945470 Arcturus Species 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
230000005778 DNA damage Effects 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
238000007400 DNA extraction Methods 0.000 description 2
238000000729 Fisher's exact test Methods 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108091060210 Heavy strand Proteins 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
102000006947 Histones Human genes 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
208000032236 Predisposition to disease Diseases 0.000 description 2
208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 2
206010071019 Prostatic dysplasia Diseases 0.000 description 2
108091008109 Pseudogenes Proteins 0.000 description 2
102000057361 Pseudogenes Human genes 0.000 description 2
108091036333 Rapid DNA Proteins 0.000 description 2
108010017842 Telomerase Proteins 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000013528 artificial neural network Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
238000001818 capillary gel electrophoresis Methods 0.000 description 2
231100000357 carcinogen Toxicity 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
231100000315 carcinogenic Toxicity 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
108091092356 cellular DNA Proteins 0.000 description 2
230000033077 cellular process Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000004720 fertilization Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000004816 latex Substances 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
238000012775 microarray technology Methods 0.000 description 2
208000012268 mitochondrial disease Diseases 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000019612 pigmentation Effects 0.000 description 2
238000000513 principal component analysis Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000004202 respiratory function Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000000779 smoke Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
102000055501 telomere Human genes 0.000 description 2
108091035539 telomere Proteins 0.000 description 2
210000003411 telomere Anatomy 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000005945 translocation Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
238000012800 visualization Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
241000020089 Atacta Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000016718 Chromosome Inversion Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000002846 Familial prostate cancer Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
108010008364 Melanocortins Proteins 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
206010033701 Papillary thyroid cancer Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
206010051246 Photodermatosis Diseases 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010063493 Premature ageing Diseases 0.000 description 1
208000032038 Premature aging Diseases 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
108091093078 Pyrimidine dimer Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000012896 Statistical algorithm Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
108010001244 Tli polymerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000018252 Tumor Protein p73 Human genes 0.000 description 1
108010091356 Tumor Protein p73 Proteins 0.000 description 1
108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000008809 cell oxidative stress Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000002508 contact lithography Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940124446 critical care medicine Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000007418 data mining Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
238000000151 deposition Methods 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
208000020735 familial prostate carcinoma Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
239000000446 fuel Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
238000013412 genome amplification Methods 0.000 description 1
238000012268 genome sequencing Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000021005 inheritance pattern Diseases 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000002865 melanocortin Substances 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000006855 networking Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
238000009595 pap smear Methods 0.000 description 1
239000000123 paper Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
238000012335 pathological evaluation Methods 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000008845 photoaging Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
210000000064 prostate epithelial cell Anatomy 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000009758 senescence Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000036555 skin type Effects 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000004575 stone Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000037316 sun-exposed skin Effects 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical class [H]S* 0.000 description 1
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000003827 upregulation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Evolutionary Biology (AREA)
Theoretical Computer Science (AREA)
Bioinformatics & Computational Biology (AREA)
Medical Informatics (AREA)
Spectroscopy & Molecular Physics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Pathology (AREA)
Microbiology (AREA)
Physiology (AREA)
Ecology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002550135A 2003-12-11 2004-12-13 Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante Abandoned CA2550135A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/732,374		2003-12-11
US10/732,374 US20050026167A1 (en)	2001-06-11	2003-12-11	Complete mitochondrial genome sequences as a diagnostic tool for the health sciences
PCT/CA2004/002124 WO2005056573A1 (fr)	2002-06-10	2004-12-13	Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante

Publications (1)

Publication Number	Publication Date
CA2550135A1 true CA2550135A1 (fr)	2005-06-23

Family

ID=36693286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002550135A Abandoned CA2550135A1 (fr)	2003-12-11	2004-12-13	Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante

Country Status (3)

Country	Link
EP (1)	EP1694695A4 (fr)
CA (1)	CA2550135A1 (fr)
WO (1)	WO2005056573A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100892253B1 (ko) *	2006-09-07	2009-04-10	(주)지노첵	인간 미토콘드리아 ｄｎａ의 변이 판별 방법과 변이 판별용폴리뉴클레오티드 프로브, ｄｎａ 칩 및 키트
KR101644661B1 (ko)	2007-11-09	2016-08-01	미토믹스 인크.	암의 검출에 사용하기 위한 약 12317-16254 잔기의 미토콘드리아 ｄｎａ 결손
WO2019241273A1 (fr) *	2018-06-11	2019-12-19	The Broad Institute, Inc.	Suivi de lignée à l'aide de mutations du génome mitochondrial et de la génomique cellulaire unique
CN114350778A (zh) *	2021-12-14	2022-04-15	迈基诺（重庆）基因科技有限责任公司	用于检测线粒体环基因突变的引物对、试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6027883A (en) *	1994-03-30	2000-02-22	Mitokor	Optimal procedure for isolation of mutant mitochondrial alleles
JP3251219B2 (ja) *	1997-10-13	2002-01-28	雅嗣田中	ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
CA2340175A1 (fr) *	1998-08-20	2000-03-02	The Johns Hopkins University School Of Medicine	Mutations mitochondriales legerement perceptibles comme marqueurs de tumeurs
EP1208225A2 (fr) *	1999-04-20	2002-05-29	Mitokor	Polymorphismes de nucleotides simples dans des genes mitochondriaux qui segregent avec la maladie d'alzheimer
SE0003286D0 (sv) *	2000-09-15	2000-09-15	Ulf Gyllensten	Method and kit for human identification
EP1397508A2 (fr) *	2001-06-11	2004-03-17	1304854 Ontario Ltd	Sequences completes du genome mitochondrial servant d'outil diagnostique dans les sciences de la sante
US20030162174A1 (en) *	2001-06-11	2003-08-28	Sutherland John W.	Detecting nucleic acid deletion sequences
SE0200817D0 (sv) *	2002-03-15	2002-03-15	Ulf Gyllensten	Method and kit for detection of mutations in mitochondrial DNA

2004
- 2004-12-13 WO PCT/CA2004/002124 patent/WO2005056573A1/fr not_active Ceased
- 2004-12-13 CA CA002550135A patent/CA2550135A1/fr not_active Abandoned
- 2004-12-13 EP EP04802299A patent/EP1694695A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
EP1694695A4 (fr)	2007-10-31
WO2005056573A1 (fr)	2005-06-23
EP1694695A1 (fr)	2006-08-30

Publication	Publication Date	Title
US10907213B2 (en)	2021-02-02	Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20050026167A1 (en)	2005-02-03	Complete mitochondrial genome sequences as a diagnostic tool for the health sciences
JP2007502113A (ja)	2007-02-08	エピジェネティク・マーカーを使用して組織または細胞タイプを鑑別するための方法および組成物
JP2007504827A (ja)	2007-03-08	１３ｑ１４染色体変化の検出
CA2450403A1 (fr)	2002-12-19	Sequences completes du genome mitochondrial servant d'outil diagnostique dans les sciences de la sante
US20070190534A1 (en)	2007-08-16	Mitochondrial sites and genes associated with prostate cancer
Yeung et al.	2018	Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome
CA2550135A1 (fr)	2005-06-23	Sequences completes du genome mitochondrial utilisees comme outil de diagnostic pour des sciences de la sante
AU2011242123B2 (en)	2013-09-12	Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
AU2002312671A1 (en)	2002-12-23	Complete mitochondrial genome sequences as a diagnostic tool for the health sciences
HK1159190A (en)	2012-07-27	Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
HK1159190B (en)	2018-03-16	Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers

Legal Events

Date	Code	Title	Description
2009-12-14	FZDE	Discontinued